InvestorWire NewsRoom


RYAH Group Inc. (CSE: RYAH) Reports on the Medical Benefits of the “Munchies”
June 10, 2021

RYAH Group Inc. (CSE: RYAH) Reports on the Medical Benefits of the “Munchies”

  • Reported on the therapeutic benefit of munchies for nausea and vomiting
  • Recorded over 14,500 sessions from patients seeking relief from nausea 
  • Munchies are a medical benefit for those going through chemotherapy or diagnosed with cachexia, also known as a wasting disorder

RYAH Group (CSE: RYAH), the leading data technology company in plant-based medicine, collects data through its IoT dose-measuring devices and AI analytics. Recently the company reported on The Therapeutic Benefit of the Munchies for Nausea and Vomiting. The full article can be found at

RYAH is uniquely positioned to collect essential data that can lead to more personalized and targeted care within the health industry. The Company partners with doctors, researchers, product suppliers, and retailers to place its top-rated apps, dose-controlled devices and services into the hands of patients and consumers. *The AI platform aggregates and correlates HIPAA-compliant dosing data from seed to consumption, allowing the company to run in-depth analytical reports. These reports help identify trends and consumer outcomes. 

Cannabis has always carried a reputation for causing a case of the “munchies.” While some might find this side effect bothersome, others turn to it for that exact reason. Since 2018, RYAH has recorded over 14,500 sessions with patients seeking relief from nausea with medical cannabis. 

Currently, cannabis is a patient-driven choice in treating nausea, vomiting, and appetite loss. Of all the conditions that patients turn to medical cannabis for, nausea and vomiting continue to be two of the most socially and legally accepted. It is common for those going through chemotherapy to seek relief and also used by those who have cachexia, a wasting disorder that causes extreme weight loss, nausea and vomiting. As evidence builds through various clinical studies, cannabinoid therapy may soon become a common doctor-recommended prescription rather than merely a patient’s request. 

RYAH first developed and commercialized its smart inhaler in 2018. Since then, it has developed a complete IoT device and data analytics platform with multiple delivery mechanisms that include the Smart-Inhaler, Smart Transdermal Patch, and the Smart Pen. 

The company has also developed data-driven platforms for doctors and for patients. RYAH MD is a remote and interactive patient-doctor collaboration and dosing administration platform that allows for real-time monitoring, appointment booking, doctor-patient video calls, science-based strain recommendations and more. For the patient and end-user, there is the PotBotApp. This medical cannabis education mobile app creates a personalized and data-driven resource of potential product matches for the user’s ailments and efficacy goals. 

RYAH is rapidly expanding and actively looking for partnerships as it takes its data-driven technology and plant-based medicine global.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).